Sanara Medtech Announced That Is Has Signed An Exclusive License Agreement With Tufts University To Develop And Commercialize Patented Technology Covering 18 Unique Collagen Peptides
Portfolio Pulse from Benzinga Newsdesk
Sanara Medtech has entered into an exclusive license agreement with Tufts University to develop and commercialize technology related to 18 unique collagen peptides. A new subsidiary, Sanara Collagen Peptides, LLC (SCP), has been formed, granting Tufts 10% ownership. SCP has exclusive rights to the patents and will pay royalties to Tufts based on net sales, with minimum annual royalties starting at $50,000 after the first year of sales and $100,000 in subsequent years.
January 03, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanara Medtech's exclusive agreement with Tufts for collagen peptide technology could lead to new product development, potentially boosting future revenues. The deal involves royalties and minimum annual payments to Tufts.
The exclusive license agreement indicates a potential for new product development and revenue streams for Sanara Medtech, which could be positively received by investors. The commitment to pay royalties and minimum annual payments to Tufts suggests confidence in the commercial viability of the technology. However, the actual impact on the stock will depend on the market's perception of the deal's potential and the company's ability to successfully develop and market the new products.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100